Indegene Q1 FY27 Revenue Surges 39.7% YoY to ₹10,631M; PAT Up 45.9% QoQ
Indegene reported Q1 FY27 revenue of ₹10,631M, up 39.7% YoY. PAT increased 45.9% QoQ to ₹1,162M. Active clients surpassed 100, reaching 105. Revenue per employee stood at $77.1K.
The substantial revenue and profit growth, along with key operational metrics like client base expansion and improved RPE, are material factors that are likely to significantly impact investor perception and the company's stock.
The company reported strong year-over-year revenue growth, significant sequential profit growth, and an expanding client base, indicating positive business performance.
Indegene Limited announced strong financial results for the quarter ended June 30, 2026, with revenue from operations reaching ₹10,631 million ($112.5 million). This represents a year-over-year (YoY) growth of 39.7% in Indian Rupees and 26.5% in US Dollars. Sequentially, revenue grew by 6.0% QoQ.
The company reported EBITDA of ₹1,795 million, achieving a margin of 16.9%, which is an 8.9% increase QoQ. Profit After Tax (PAT) stood at ₹1,162 million, with a margin of 10.9%, marking a significant 45.9% increase QoQ.
Key operational highlights include crossing the 100-active client milestone, with the number increasing by 14 sequentially to 105. The number of clients generating $10 million or more in annual revenue expanded by 2 sequentially to 12. Revenue per Employee (RPE) strengthened to $77.1K, noted as the highest among peers.
Manish Gupta, Chairman and CEO, stated that the company started FY27 strongly with its best sequential first-quarter USD revenue growth in four years and an expanding client base. He emphasized improvements in productivity and deepened client relationships, with a focus on developing differentiated products, solutions, and GenAI-powered technologies.
Suhas Prabhu, CFO, highlighted the 39.7% YoY revenue growth in INR and 26.5% in USD, attributing the increase in active clients to investments in sales and go-to-market teams. He also noted sequential improvements in EBITDA and PAT margins, expecting further profitability strengthening in the second half of the year as investments mature and engagements scale.
What to do with a filing like this
Indegene Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indegene Limited. Read the original for the full detail.